Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SNCA | P37840 | 2/20 | 0.32 |
| ▸ | CCKAR | P32238 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | TRIP13 | Q15645 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726611 | 0.86 | IGF1R (0.44) | LMNARAB9A | |
| SCHEMBL3734828 | 0.86 | IGF1R (0.44) | LMNARAB9A | |
| SCHEMBL3727906 | 0.85 | IGF1R (0.37) | ALDH1A1LMNARAB9ASMN1; SMN2HPGD | |
| SCHEMBL3727715 | 0.73 | IGF1R (0.35) | — | |
| SCHEMBL3724832 | 0.73 | IGF1R (0.35) | ALDH1A1SMN1; SMN2HPGDHTTNAMPT | |
| SCHEMBL3732092 | 0.73 | IGF1R (0.38) | NAMPT | |
| Trifluoroacetic Acid SCHEMBL4885943 | 0.69 | SMO (0.50) | ALDH1A1 | |
| SCHEMBL3728745 | 0.69 | IGF1R (0.40) | SMN1; SMN2HPGD | |
| SCHEMBL4879679 | 0.69 | NR1H2 (0.36) | ALDH1A1LMNARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL5483127 | 0.68 | KDM4E (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1621535-A1 | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021029-A1 | Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | PRKAR2B, PRKG2, PRKG1 | ALDH1A1 3245/4885LMNA 2251/4885RAB9A 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.